IPO March 2020 at First North
STAYBLE’S NEW ISSUE WAS SUBSCRIBED TO 436%
Andreas Gerward, CEO of Stayble Therapeutics, comments
We are considerably strengthened by the great interest from investors in our new issue of SEK 35 million, which was oversubscribed with over SEK 150 million by over 4,000 interested investors. We are grateful for the confidence shown by the market which enables the start of the Phase 2b clinical trial in Q2 2020.
Together with my team as well as with new and old shareholders, I look forward to take Stayble through the next major step in the development of a new treatment that has the potential to completely change how chronic disc-related low back pain will be treated in the future.
———————————— Previous information ————————————
Stayble Therapeutics AB aim to list the Company’s shares on Nasdaq First North Growth Market. In connection with the listing, the Company carries out a new unit issue of approximately SEK 35 million, before deduction of transaction costs, where each unit consists of one share and one warrant free of charge.
The full terms and conditions for the Offering is available in a prospectus (only in Swedish), see below.
Nasdaq Stockholm AB has approved Stayble’s application for admission of trading of the Company’s shares and warrants on Nasdaq First North, provided that the Company meets the conditions in Nasdaq First North’s rulebook such as distribution requirements, no later than the first day of trading which is expected at March 9, 2020.